PMID- 33192966
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240330
IS  - 1664-2295 (Print)
IS  - 1664-2295 (Electronic)
IS  - 1664-2295 (Linking)
VI  - 11
DP  - 2020
TI  - Cannabidiol in the Treatment of Epilepsy: A Focused Review of Evidence and Gaps.
PG  - 531939
LID - 10.3389/fneur.2020.531939 [doi]
LID - 531939
AB  - Approximately one third of epilepsy patients do not become seizure free with 
      antiseizure medications. This treatment gap motivates research for new 
      therapeutic options, such as cannabidiol (CBD). CBD differs from other cannabis 
      derivatives because of its consistent efficacy and lack of a psychoactive effect. 
      CBD can be recommended as adjunctive therapy in patients with Dravet and 
      Lennox-Gastaut syndromes. The most common adverse effects (AEs) are drowsiness, 
      reduced appetite, diarrhea, and vomiting. Transaminase elevation is the most 
      common AE that leads to CBD discontinuation. Coadministration with valproate may 
      increase the risk of hepatotoxicity. The combination of CBD and clobazam may 
      increase both the effectiveness and the risk of AEs associated with these drugs. 
      The most striking gaps in knowledge are the efficacy and optimal dose of CBD for 
      adults with focal epilepsies, the long-term safety of CBD use, and strategies to 
      improve access to CBD for people living with epilepsy.
CI  - Copyright (c) 2020 Silva, Del Guerra, de Oliveira Lelis and Pinto.
FAU - Silva, Guilherme Diogo
AU  - Silva GD
AD  - Department of Neurology, Hospital das Clinicas da Faculdade de Medicina da 
      Universidade de Sao Paulo, Sao Paulo, Brazil.
FAU - Del Guerra, Felipe Borelli
AU  - Del Guerra FB
AD  - Department of Neurology, Hospital das Clinicas da Faculdade de Medicina da 
      Universidade de Sao Paulo, Sao Paulo, Brazil.
FAU - de Oliveira Lelis, Maira
AU  - de Oliveira Lelis M
AD  - Federal University of Amazonas, Manaus, Brazil.
FAU - Pinto, Lecio Figueira
AU  - Pinto LF
AD  - Department of Neurology, Hospital das Clinicas da Faculdade de Medicina da 
      Universidade de Sao Paulo, Sao Paulo, Brazil.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201019
PL  - Switzerland
TA  - Front Neurol
JT  - Frontiers in neurology
JID - 101546899
PMC - PMC7604476
OTO - NOTNLM
OT  - cannabidiol
OT  - efficacy
OT  - epilepsy
OT  - evidence
OT  - gaps
OT  - review
OT  - safety
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
PMCR- 2020/10/19
CRDT- 2020/11/16 08:46
PHST- 2020/02/02 00:00 [received]
PHST- 2020/08/17 00:00 [accepted]
PHST- 2020/11/16 08:46 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
PHST- 2020/10/19 00:00 [pmc-release]
AID - 10.3389/fneur.2020.531939 [doi]
PST - epublish
SO  - Front Neurol. 2020 Oct 19;11:531939. doi: 10.3389/fneur.2020.531939. eCollection 
      2020.